Related Experiment Videos
[Behavioral effects of febarbamate (MS-543): evaluation by ambulatory activity, active avoidance and passive
1Division for Behavior Analysis, Gunma University School of Medicine, Maebashi, Japan.
Abstract:
Febarbamate (MS-543: 100 and 10000 mg/kg, p.o.) neither produced significant change in the mouse's ambulatory activity after the single administration nor modified the ambulation-increasing effects of the following drugs: methamphetamine (2 mg/kg, s.c.), apomorphine (0.5 mg/kg, s.c.) and scopolamine (0.5 mg/kg, s.c.). MS-543 (100 and 1000 mg/kg, p.o.) scarcely affected the established active avoidance response in mice under a discrete shuttle avoidance situation. However, MS-543 (1000 mg/kg, p.o.) tended to enhance the decrease in response and/or avoidance rates induced by chlorpromazine (2 mg/kg, s.c.) and physostigmine (0.2 mg/kg, s.c.). Finally, the disruption of the step-through passive avoidance response induced by pre-training administration of scopolamine (0.5 mg/kg, s.c.) in a one trial task was reduced when MS-543 was administered before the scopolamine administration. However, the post-training administration of MS-543 was without effect on the scopolamine-induced disruption of the avoidance. Furthermore, no significant effect of MS-543 was observed in the multi-trial passive avoidance task. The present results suggest that MS-543 activates cholinergic function and possesses a slight sedative action.
Insights
Febarbamate (MS-543) did not significantly alter mouse activity or the effects of stimulant drugs. However, it showed potential in improving memory and cognitive function in certain tests, suggesting cholinergic activation.
Area of Science:
- Neuropharmacology
- Behavioral Neuroscience
Background:
- Understanding the central nervous system effects of novel compounds is crucial for developing new therapeutic agents.
- Febarbamate (MS-543) is a compound whose neuropharmacological profile requires detailed investigation.
Purpose of the Study:
- To evaluate the effects of Febarbamate (MS-543) on motor activity, learning, and memory in rodent models.
- To investigate the potential interaction of MS-543 with known neuroactive drugs and its impact on cholinergic systems.
Main Methods:
- Administration of Febarbamate (MS-543) at various doses (100 and 10000 mg/kg, p.o.) to mice.
- Assessment of ambulatory activity, active avoidance responses (discrete shuttle box), and passive avoidance responses (step-through and multi-trial tasks).
- Evaluation of MS-543's effects in conjunction with other drugs including methamphetamine, apomorphine, scopolamine, chlorpromazine, and physostigmine.
Main Results:
- MS-543 did not significantly alter baseline ambulatory activity or the stimulant effects of methamphetamine, apomorphine, or scopolamine.
- MS-543 showed a tendency to enhance the disruptive effects of chlorpromazine and physostigmine on active avoidance at a high dose (1000 mg/kg).
- Pre-training administration of MS-543 reduced scopolamine-induced deficits in passive avoidance, while post-training administration had no effect. No significant effects were observed in multi-trial passive avoidance.
Conclusions:
- Febarbamate (MS-543) appears to possess a slight sedative action and does not significantly interfere with motor activity or stimulant drug effects.
- The results suggest that MS-543 activates cholinergic function, particularly evident in its ability to mitigate scopolamine-induced memory impairment in a passive avoidance task.